<abstract xmlns="http://www.w3.org/1999/xhtml">

<bold>Background</bold>: To study the expressions of transforming growth factor-β1 (TGF-β1) and vascular endothelial growth factor (VEGF) in patients with acute myeloid leukemia (AML) and their values for prognosis.
<bold>Methods</bold>: A total of 120 AML patients treated from January 2015 to December 2018 were selected. Bone marrow mononuclear cells were isolated. The expressions of TGF-β1 and VEGF were detected by RT-PCR, and their associations with clinical characteristics were analyzed. The overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method. The risk factors for prognosis were analyzed through the Cox proportional hazards model.
<bold>Results</bold>: The AML group had significantly lower relative expression of TGF-β1 and higher relative expression of VEGF than those of the control group (P&lt;0.05). TGF-β1 and VEGF levels were significantly correlated with white blood cell count, hemoglobin, platelets, and peripheral blood juvenile cells (P&lt;0.05). TGF-β1 level was higher and VEGF level was lower in the patients with complete response than those in the patients with partial response and no response (P&lt;0.05). Both OS and DFS of the patients with high TGF-β1 expression were better than those of the patients with low TGF-β1 expression, while they were also superior among the patients with low VEGF expression (P&lt;0.05). Platelets, TGF-β1 and VEGF were independent influencing factors for OS, and white blood cells, TGF-β1 and VEGF were independent influencing factors for DFS (P&lt;0.05).
<bold>Conclusions</bold>: AML patients have decreased expression of TGF-β1 and increased expression of VEGF, and such changes are closely associated with the prognosis of AML.
</abstract>

Background: To study the expressions of transforming growth factor-β1 (TGF-β1) and vascular endothelial growth factor (VEGF) in patients with acute myeloid leukemia (AML) and their values for prognosis.
Methods: A total of 120 AML patients treated from January 2015 to December 2018 were selected. Bone marrow mononuclear cells were isolated. The expressions of TGF-β1 and VEGF were detected by RT-PCR, and their associations with clinical characteristics were analyzed. The overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method. The risk factors for prognosis were analyzed through the Cox proportional hazards model.
Results: The AML group had significantly lower relative expression of TGF-β1 and higher relative expression of VEGF than those of the control group (P<0.05). TGF-β1 and VEGF levels were significantly correlated with white blood cell count, hemoglobin, platelets, and peripheral blood juvenile cells (P<0.05). TGF-β1 level was higher and VEGF level was lower in the patients with complete response than those in the patients with partial response and no response (P<0.05). Both OS and DFS of the patients with high TGF-β1 expression were better than those of the patients with low TGF-β1 expression, while they were also superior among the patients with low VEGF expression (P<0.05). Platelets, TGF-β1 and VEGF were independent influencing factors for OS, and white blood cells, TGF-β1 and VEGF were independent influencing factors for DFS (P<0.05).
Conclusions: AML patients have decreased expression of TGF-β1 and increased expression of VEGF, and such changes are closely associated with the prognosis of AML.

Expressions of TGF-β1 and VEGF in patients with acute myeloid leukemia and associations with prognosis

Affiliated Danyang Hospital of Nantong University

Hematology, Affiliated Hospital of Jiangsu University

Revista Romana de Medicina de Laborator

This work is licensed under the Creative Commons Attribution 4.0 International License.

Background: To study the expressions of transforming growth factor-β1 (TGF-β1) and vascular endothelial growth factor (VEGF) in patients with acute myeloid...

Expressions of TGF-β1 and VEGF in patients with acute myeloid leukemia and associations with prognosis

Pubblicato online: 18 lug 2022

Pagine: 273 - 280

Ricevuto: 26 nov 2021

Accettato: 06 giu 2022

DOI: https://doi.org/10.2478/rrlm-2022-0026

Parole chiave
TGF-β1, VEGF, acute myeloid leukemia, prognosis

© 2022 Yan Xu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Expressions of TGF-β1 and VEGF in patients with acute myeloid leukemia and associations with prognosis

Pubblicato online: 18 lug 2022

Pagine: 273 - 280

Ricevuto: 26 nov 2021

Accettato: 06 giu 2022

DOI: https://doi.org/10.2478/rrlm-2022-0026

Parole chiaveTGF-β1, VEGF, acute myeloid leukemia, prognosis

© 2022 Yan Xu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Parole chiave
TGF-β1, VEGF, acute myeloid leukemia, prognosis